Skip to main content

Table 1 Summary of therapeutic antibodies combined with inhibition of autophagy

From: Targeting autophagy to overcome drug resistance: further developments

Therapeutic antibodies Targets Combination therapy Indications References
Rituximab CD20 CQ Non-Hodgkin lymphoma [151]
Bevacizumab VEGF CQ HCC [152]
Cetuximab EGFR CQ Vulvar squamous carcinoma [147]
   Overexpressed Bcl-2 Colorectal adenocarcinoma  
   siRNA ATG7 Lung adenocarcinoma  
   siRNA Beclin1   
Gemtuzumab ozogamicin CD33 PP242 Acute myeloid leukemia [153]
   AZD2014   [154]
DN30 Met Baf Cardiomyoblasts [155]
DO24     
Trastuzumab HER2 CQ Breast cancer [148]
Milatuzumab CD74 FTY720 Mantle cell lymphoma [156]
Tositumomab CD20 Overexpressed Bcl-2 B cell malignancies [157]
   siRNA Beclin1   
   siRNA ATG 12   
CH12 EGFRvIII siRNA ATG7 HCC [158]
   siRNA Beclin1   
β2M mAb β2-microglobulin Bortezomib Multiple myeloma [159]
PD-1 mAb PD-1 Pemetrexed + sildenafil Non-small cell lung cancer [160]
CTLA4 mAb CTLA4